The second casestudy was ADD (compound 15d in ref ), a merged human butyrylcholinesterase(hBChE) inhibitor/cannabinoid receptor 2 (hCB2R) ligand and a therapeutictarget for preventing learning impairments in Alzheimer’s disease(Figure B). The baseline multistep modelfailed to identify a synthetic route, while the mixed fine-tuned model predicts retrosynthetic disconnections similar to the literatureroute (Figure ). This evidence concerns the gene CNR2 and early-onset autosomal dominant Alzheimer disease.